Psychedelics biotech firm, Enveric Biosciences has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, British Columbia-based biopharma company MindBio Therapeutics Corp CSE: MBIO, which is pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines.
The news comes on the heels of Enveric entering into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers.
